Metrics to compare | WANBURY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWANBURYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 13.6x | 28.8x | −0.2x | |
PEG Ratio | 2.93 | 0.48 | 0.00 | |
Price/Book | 4.3x | 3.2x | 2.6x | |
Price / LTM Sales | 1.0x | 4.1x | 2.8x | |
Upside (Analyst Target) | - | 11.4% | 65.0% | |
Fair Value Upside | Unlock | −2.8% | 9.6% | Unlock |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API portfolio includes Metformin Hcl, Sertraline Hcl, Tramadol Hcl, Mefenamic Acid, Metformin Hcl DC, Diphenhydramine Citrate, Paroxetine, Diphenhydramine Hcl, and Anaesthetic API. The company was founded in 1988 and is headquartered in Navi Mumbai, India.